Tucotuzumab celmoleukin

From WikiMD.org
Jump to navigation Jump to search

Tucotuzumab celmoleukin

Tucotuzumab celmoleukin (pronunciation: too-koh-TOO-zoo-mab sel-moh-LOO-kin) is a biopharmaceutical drug used in the treatment of certain types of cancer. It is a monoclonal antibody that has been engineered to stimulate the body's immune system to attack cancer cells.

Etymology

The name "Tucotuzumab celmoleukin" is derived from the International Nonproprietary Name (INN) system for pharmaceutical substances. "Tucotuzumab" indicates that it is a monoclonal antibody (mab) used for neoplastic diseases (tuzumab). "Celmoleukin" is a term used to describe a molecule that has been engineered to include a cytokine, in this case, interleukin-2 (IL-2).

Mechanism of Action

Tucotuzumab celmoleukin works by binding to the EGFR on the surface of cancer cells. This binding triggers an immune response that leads to the destruction of the cancer cells. The addition of the IL-2 molecule enhances this immune response, making the drug more effective.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski